RECRUITING

PRISM: Patient Experiences With PET Imaging in Prostate Cancer

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.

Official Title

Optimizing Prostate Cancer Care: Integrating Risks, Benefits and Patient Experiences in the New Era of Molecular Imaging

Quick Facts

Study Start:2024-07-25
Study Completion:2028-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06523777

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Documented diagnosis of prostate cancer
  2. * Scheduled for their FIRST PSMA PET scan for prostate cancer
  3. * English-speaking
  4. * Willing and able to complete 4 surveys electronically or on paper at 3 timepoints (within 1 month after PET scan, 3-6 months, 12 months)
  5. * Able to use mobile device (smartphone or tablet) or computer with web access to complete study surveys or able to complete paper surveys
  1. * Lack of access to a mobile device (smartphone or tablet) or computer with web access or unable to receive surveys by mail.
  2. * Unable to give consent and be enrolled
  3. * PET scan is being conducted within a clinical trial

Contacts and Locations

Study Contact

Michael S Leapman, MD
CONTACT
203-785-3128
michael.leapman@yale.edu
Sarah Linsky, MPH
CONTACT
475.375.6129
sarah.linsky@yale.edu

Principal Investigator

Michael Leapman, MD
PRINCIPAL_INVESTIGATOR
Yale School of Medicine

Study Locations (Sites)

Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center
Bridgeport, Connecticut, 06611
United States
Griffin Hospital
Derby, Connecticut, 06418
United States
Yale New Haven Health Greenwich Hospital
Greenwich, Connecticut, 06830
United States
Radiology and Biomedical Imaging - New Haven - Smilow Cancer Hospital (North Pavilion):
New Haven, Connecticut, 06520
United States
Saint Raphael's Radiology and Biomedical Imaging, Basement Location.
New Haven, Connecticut, 06520
United States
Yale New Haven Health Lawrence & Memorial Hospital
New London, Connecticut, 06320
United States
Yale New Haven Health Westerly Hospital
Westerly, Rhode Island, 02891
United States

Collaborators and Investigators

Sponsor: Yale University

  • Michael Leapman, MD, PRINCIPAL_INVESTIGATOR, Yale School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-25
Study Completion Date2028-07

Study Record Updates

Study Start Date2024-07-25
Study Completion Date2028-07

Terms related to this study

Additional Relevant MeSH Terms

  • Prostate Cancer